Fate Therapeutics
FATE
39 hedge funds and large institutions have $117M invested in Fate Therapeutics in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 2 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 2
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
125% more capital invested
Capital invested by funds: $51.9M → $117M (+$64.7M)
56% more funds holding
Funds holding: 25 → 39 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$12M |
| 2 |
BC
Broadfin Capital
New York
|
+$7.36M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.72M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$5.29M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$148K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$99K |
| 3 |
SIM
Spark Investment Management
New York
|
-$61K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$17K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$11.8K |
FATE Hedge Fund Activity: Q2 2015 in Review
39 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2015, worth a combined $117M — up 125% from $51.9M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FATE positions and 5 closed out — a net gain of 14 holders — while 14 added to existing stakes and 2 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $12M. The largest seller was Goldman Sachs, cutting an estimated $148K.
- 39 institutional investors held Fate Therapeutics (FATE) as of Q2 2015, up from 25 in Q1 2015.
- Funds reported $117M of Fate Therapeutics stock for Q2 2015, up 125% quarter-over-quarter.
- 19 funds opened new Fate Therapeutics positions in Q2 2015 and 5 closed out, a net change of +14 holders.
- The largest Fate Therapeutics buyer in Q2 2015 was Redmile Group, an estimated $12M added.
- The largest Fate Therapeutics seller in Q2 2015 was Goldman Sachs, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2015.